Despite the dramatic increase in global access to human immunodeficiency virus (HIV) treatment and prevention interventions, HIV epidemics among men who have sex with men (MSM) and transgender women (TW) have continued to expand in many countries, including those in Latin America (1, 2) . In the Americas, MSM and TW represent the subpopulations with the largest proportion of new HIV infections per year (1, 3, 4) . An analysis of 15 Latin American countries demonstrated that MSM were 33 times more likely to be HIV-infected than heterosexual men in the general population (3) . Globally, TW are almost 50 times more likely to be HIV-infected than adults of reproductive age (4) , with an estimated HIV prevalence of 30% in Peru (5) .
Existing HIV prevention interventions for MSM and TW (e.g., consistent condom use, serosorting, HIV testing and counseling, and individual-level behavioral interventions to reduce risk behavior) have shown varying degrees of effectiveness, but it is becoming increasingly clear that these strategies are not sufficient to end the epidemic (6) . Biomedical strategies, such as the use of antiretroviral therapy (ART) by HIV-negative individuals as preexposure prophylaxis (PrEP) (7) , are efficacious in preventing HIV acquisition. However, barriers to programmatic implementation of PrEP in limited-resource settings include concerns about cost, effectiveness, and risk compensation (8) . In addition, use of ART for treatment rather than for PrEP will likely be prioritized, and regulatory approvals for ART as PrEP can delay in-country implementation. For example, although initial studies of PrEP were conducted in Peru, it was not approved there until April 2016 (9) and thus was unavailable during our study.
ART for subjects with established HIV infection prevented onward HIV transmission by up to 96% (10) . Two observational studies including HIV-discordant MSM couples found that, following the provision of ART to the infected partner, there were no documented HIV transmissions despite almost 40,000 acts of condomless anal intercourse (11, 12) . There has been little research on the efficacy of treatment as prevention (TasP) among TW specifically. Hypothetically, early ART initiation could markedly reduce HIV transmission during acute and recent infection when plasma and genital/rectal HIV viral loads are high. It is estimated that up to 22% of onward transmissions among MSM in Peru occur during acute infection (13) . The potential benefit of such a strategy may be high-modeling studies predict that transmission during the acute infection period could account for up to one-half to two-thirds of new infections among MSM (14) .
Based on these and other results, the World Health Organization (WHO) has recommended providing ART to all HIVinfected persons regardless of CD4-positive cell count for the benefit of that individual and to prevent onward transmission (i.e., TasP) (15) . TasP offers advantages over other prevention interventions that reduce population-level HIV incidence only if their uptake reaches high coverage among HIV-negative individuals. TasP strategies generally focus on treatment of persons diagnosed using yearly (or less frequent) serological testing. We sought to assess whether TasP efficacy could be improved in high-risk populations through earlier HIV detection and rapid initiation of treatment.
The Sabes Study ("¿Sabes?" in Spanish means "Do you know?") sought to optimize a "seek, test, treat, and retain" strategy (16) to reduce HIV transmission through reduction of high-risk sexual behaviors and early initiation of ART in Peruvian MSM and TW with acute or recent HIV infection. Our hypothesis was that intervening early, especially during acute infection, through the provision of ART would markedly reduce HIV transmission in this population.
Here we outline the methods of the study and provide details on participant recruitment. In the Sabes Study, we sought to evaluate the following specific activities:
1. Testing for HIV frequently and treating newly diagnosed HIVinfected MSM and TW. By increasing HIV testing frequency and coverage, we sought to identify HIV infection shortly after acquisition and to initiate behavioral and ART interventions early to reduce onward HIV transmission. 2. Quantifying the impact of timing of early ART initiation on HIV viral load in plasma, semen, and rectal secretions. These data will be used to model the potential benefits of early ART in reducing onward transmission among MSM and TW populations. 3. Analyzing HIV phylogenetic data and linked questionnaire data in order to assess sexual networks and their relationship to alcohol and drug use. We are sequencing HIV from plasma collected shortly after HIV acquisition and conducting phylogenetic analysis; clusters of highly related sequences may indicate onward HIV transmission shortly after HIV acquisition (i.e., prior to the development of sequence diversity) (14) . Further analysis integrating phylogenies with geospatial and behavioral data from monthly questionnaires (alcohol and drug use, sexual behaviors, and meeting sexual partners at social venues (e.g., bars)) may provide insights into drivers of onward transmission. 4. Modeling with both deterministic and agent-based methods to assess network dynamics and the potential populationlevel impact of our TasP interventions. We are developing HIV epidemic models incorporating study data to model the impact of 2 intervention components: increased testing frequency and earlier treatment initiation. Our models may reveal additional special considerations that underlie transmission dynamics in MSM and TW.
METHODS
Sabes was a multisite study that investigated the feasibility and benefits of incorporating frequent testing for acute and recent HIV infection and rapid linkage to care at community testing and treatment sites in Lima, Peru.
Study sites
There were 4 research sites in the Sabes Study; 3 were part of HIV research organizations (2 from the Health and Education Civil Association (IMPACTA) and 1 from Asociación Vía Libre), and 1 was a community-based organization, Epicentro. The Alberto Barton Health Center (Callao, Peru), a Ministry of Health clinic that offers services to MSM and TW, also referred a small number of participants.
Study population
Persons who were male at birth, who reported having had sex with a male partner in the past 12 months, and who were ≥18 years of age were eligible for participation. In addition, they must have been unaware of their HIV status and have been at high risk for acquiring HIV because 1) they were a partner of a person with newly diagnosed acute or recent HIV infection; 2) they were seeking HIV testing because they had symptoms of acute retroviral syndrome; or 3) they reported high-risk sexual behavior, defined as any of the following (17): a) no condom use during anal intercourse in the last 6 months; b) anal intercourse with more than 5 male sex partners during the last 6 months; c) self-identification as a sex worker; d) diagnosis of a sexually transmitted infection during the last 6 months or at screening; or e) being a sexual partner of an HIV-infected man or TW in the last 6 months.
Definition of acute and recent HIV infections
Acute HIV infection was operationally defined as a positive plasma HIV RNA test in a person with a negative third-generation HIV antibody test. Recent HIV infection was diagnosed by means of a positive third-generation rapid HIV test (confirmed by a separate enzyme immunoassay) with a documented negative third-generation HIV-antibody or HIV-RNA test in the previous 3 months. infection, and 3) if acute/recent infection is identified, enroll those subjects in a randomized study of immediate initiation of ART versus deferred initiation ( Figure 1 ).
Step 1: Screen to identify HIV-negative individuals. All persons voluntarily visiting a participating clinic were asked about recent sexual activity, HIV risk factors, and their main reason for visiting the clinic. In addition, peer educators visited previously identified social venues (e.g., saunas, adult movie theaters, sexwork areas, discotheques, bars, beauty parlors, sporting events) to provide information about HIV and sexually transmitted infection prevention and to refer potential participants to study sites. Finally, a number of participants from the 2011 Peruvian Biobehavioral Survey (18) were invited to join the Sabes Study. MSM and TW were assessed for eligibility prior to HIV testing.
To enroll in step 1, each participant had to be willing and able to provide informed consent for participation, including HIV testing, and to be recontacted if testing indicated acute or recent HIV infection, or to continue to be retested if the initial test result was negative (step 2). If testing indicated acute or recent HIV infection, the participant was asked to enroll in a randomized study of immediate versus deferred ART (step 3). TW who reported the use of estrogens or antiandrogens in the last 3 months were not eligible, because use of these drugs could impair provision of semen specimens collected as part of the protocol for HIV-infected participants (step 3). Persons with any physical, medical, occupational, or other condition that, in the judgment of the investigators, would interfere with or serve as a contraindication to protocol adherence or assessment of safety were excluded from participation.
HIV screening was conducted on whole blood using Alere Determine HIV-1/2 (Alere Inc., Waltham, Massachusetts), a point-of-care third-generation HIV antibody test. Blood samples that were negative for HIV antibodies were pooled and tested for HIV RNA with a nucleic acid amplification test using a Liat HIV Quant Assay (IQuum, Inc., Marlborough, Massachusetts). Positive pools were deconvoluted to identify HIV-positive samples, using a fourth-generation HIV enzyme immunoassay
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Step 1 (Bio-Rad Laboratories, Hercules, California) or HIV RNA tests. The Abbott RealTime HIV-1 test (Abbott Laboratories, Lake Bluff, Illinois) was used to confirm HIV infection. Participants completed a structured computer-assisted selfinterview on demographic factors, sexual behavior, social venue attendance, drug and alcohol use, and stigma and coping. All participants were also tested for syphilis using a rapid plasma reagent test (RPR QuickTest; Stanbio Laboratory, Boerne, Texas). Positive results were confirmed by means of a Treponema pallidum particle agglutination assay (TPHA Test Kit DR0530; Oxoid Microbiology Products Ltd., Basingstoke, United Kingdom). Participants with acute or recent HIV, as defined in this study, were invited to participate in step 3. Persons found to have established HIV infections (>3 months since acquisition) were referred to local health-care providers to receive the local standard of care or to participate in other studies if available. HIV-negative subjects were invited to continue their participation in step 2.
Step 2: Enroll HIV-negative subjects from step 1 for monthly HIV testing. MSM and TW found to have no HIV infection in step 1 were given free condoms, lubricant, and standard riskreduction counseling. They were asked to visit the study center monthly for a 2-year period for HIV retesting and to complete a computer-assisted self-interview questionnaire on social venue attendance, substance use, and sexual behaviors. Participants diagnosed with acute or recent HIV infection were invited to participate in step 3. HIV-positive persons identified more than 3 months after their last negative HIV RNA test were not eligible, because infection within the past 3 months could not be unambiguously determined in these individuals. They were referred to appropriate facilities to receive the local standard of care or to participate in other available studies.
Step 3: Enroll subjects with early HIV infection in immediate or deferred ART. Persons with acute or recent HIV infection diagnosed in steps 1 or 2 were enrolled in a 48-week randomized study of immediate ART versus deferred ART. An additional 12 subjects with recent HIV infection were enrolled directly in step 3 from the Alberto Barton Health Center. All newly diagnosed HIV-positive participants were linked to care at study clinics as quickly as possible, either by referral after diagnosis of recent infection by point-of-care assays or through peer health navigators who contacted patients shortly after laboratory diagnosis of acute infection. Consenting volunteers were administered a structured computer-assisted interview questionnaire on drug use history (19) ; alcohol-use disorders (20) ; health status (21); anxiety and depression (22) ; social support, stigma, and disclosure; and medical care (hospitalization and emergency room use, access to care, and barriers to care). Participants were randomized one-to-one using blocks of 2 or 4 to start ART immediately or to defer ART initiation until 24 weeks after enrollment (when setpoint viral load is established), unless Peruvian criteria for ART initiation were met earlier (CD4-positive cell count ≤500 cells/mm 3 ; changed from ≤350 cells/mm 3 in December 2014) or their illness was diagnosed as meeting WHO clinical stage 3 or 4. Thus, all participants received ART either before or at the time they met criteria for ART initiation in Peru. The ART regimen was coformulated tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg/efavirenz 600 mg, 1 tablet taken orally daily. Participants were switched to alternate WHO-recommended regimens for intolerance or toxicity. Participants experiencing treatment failure (i.e., not achieving more than 1 log 10 drop in plasma HIV RNA copies per mL after 16 weeks of treatment; not achieving an HIV RNA level below 50 copies/ mL after 24 weeks of treatment; or having an HIV RNA level greater than 400 copies/mL upon 2 consecutive measurements after having achieved an HIV RNA level below 50 copies/mL) were switched to an alternate WHO-recommended regimen 
Protection of human subjects
The study protocol, informed consent forms, and recruitment materials were approved by institutional review boards at the Fred Hutchinson Cancer Research Center, the Health and Education Civil Association, and the Asociación Vía Libre, in compliance with all applicable Peruvian and US federal regulations governing the protection of human subjects. All study participants provided written consent in Spanish, their native language, to participate in the study. Implementation of the study was authorized by the Peruvian National Institute of Health, and the study is registered with ClinicalTrials.gov (https://clinicaltrials.gov/; trial NCT01815580).
RESULTS
Step 1
Recruitment for step 1 began in July 2013 and was completed in September 2015 with the testing of 3,337 high-risk participants (Table 1) . Over 93% of the subjects were identified through clinic screening of the general population of MSM and TW; the remaining 7% were identified from the 2013 Peruvian Biobehavioral Survey (18) . The overall prevalence of HIV among the participants at baseline was 19.5%, although there were marked differences between the 2 source populations: 20.7% for the general screening population and only 3.1% for the biobehavioral survey population. This difference occurred because subjects were tested for HIV in the Peruvian Biobehavioral Survey and only HIV-uninfected individuals were referred for rescreening in the Sabes Study several months later. Although SilvaSantisteban et al. (5) reported higher HIV prevalence among TW than among MSM in Peru, HIV prevalences in the Sabes TW and MSM were similar (19.3% and 19.7%, respectively); thus, they were combined for this analysis.
The 2 most common risk factors for study inclusion, "no condom use during last anal intercourse" and "anal intercourse with more than 5 sexual partners in the last 6 months," were reported by 57% and 37% of participants, respectively. The main reason for visiting the clinic, "thought exposed to HIV," was reported by 42% of the participants and by 41% of those who were HIVnegative. The next most common reason, "referred by a peer educator," was reported by 21% of the tested subjects and 22% of those who were HIV-negative. All other reasons were mentioned by less than 3% of the tested subjects, and the distributions were similar for both the tested and HIV-negative subjects.
Step 2 Of the 2,685 HIV-negative MSM and TW identified in step 1, a total of 2,109 (78.5%) enrolled in step 2 for repeated monthly HIV testing (Table 2) . Follow-up for step 2 ended in May 2016, so follow-up for some of the more recently enrolled participants was truncated at less than 24 months; 256 cases of HIV infection were identified in step 2. However, because the length of the interval since their last negative test was greater than 3 months, 54 of these HIV-positive subjects could not be categorized as having recent infections and were therefore ineligible to enroll in step 3, which left 202 eligible participants.
In general, the step 2 participants were young (44% were below age 25 years), were well-educated (60% had at least some postsecondary schooling), had only marginal incomes (65% reported monthly incomes below US$400, the customary poverty line for Peru), and identified predominantly as homosexual (49%). Almost half (42%) reported both insertive and receptive sex roles, and just over half (53%) reported drinking behavior consistent with an alcohol-use disorder (score ≥8 on the Alcohol Use Disorders Identification Test).
Participants who enrolled and did not enroll differed with regard to age, education, income, sexual identity, and sexual role ( Table 2) . Compared with the nonenrollees, persons who enrolled in step 2 were slightly older, more educated, and more likely to self-identify as homosexual, and they differed in reported sexual role. Retention of participants in the cohort was high: After 3 months, 87% were still returning for retesting, and after 12 months this proportion was 62% (Figure 2 ).
Step 3
A total of 256 eligible subjects with acute or recent HIV infections were identified during the study-the majority (78%) from rescreening in step 2, and the remainder from initial testing in step 1 and referral from the Alberto Barton Health Center ("Barton clinic") ( Figure 1 ). Forty HIV-positive subjects either declined to enroll in step 3 or were excluded from enrollment in step 3 because of health issues: 6 from step 1 and 34 from step 2. An additional 12 eligible participants were recruited from the Barton clinic and enrolled in step 3. The resulting total enrollment in step 3 was 216 persons.
The enrolled population closely reflected the eligible population with regard to all of the characteristics examined (Table 3) . The denominator for each quarterly data point was equal to the number of subjects who were eligible for retesting at that time of observation. This excludes subjects who became positive for human immunodeficiency virus during the previous quarters, as well as a small number of participants whose follow-up was truncated when follow-up was terminated prior to the completion of 2 years of observation.
One-third (35%) of the enrolled HIV-positive subjects had acute infections, and two-thirds (65%) had recent infections. Participants in these 2 categories were then randomized separately into treatment groups to receive ART immediately or beginning at 24 weeks (Figure 1 ).
DISCUSSION
Initial testing of study participants in step 1 and their enrollment in periodic retesting (step 2) was completed in September 2015. Enrollment of participants identified with acute and recent . P values were calculated on nonmissing data. b An additional 54 HIV-seropositive subjects were identified during step 2 rescreening. However, the elapsed time since their previous screening was greater than 3 months, so they could not be classified as "recently infected"; therefore, they were not eligible to enroll in step 3.
c Postsecondary includes Peruvian higher technical education as well as college/university. d AUDIT score ≥8 is indicative of an alcohol-use disorder.
HIV infections in step 3 was completed in May 2016. Followup of step 3 participants was completed in April 2017.
Ongoing step 3 analyses
In ongoing step 3 analyses, we are engaging in the following activities.
Estimation of the impact of immediate and deferred ART on the decay dynamics of HIV viral load. We are measuring viral load in plasma, semen, and rectal secretions collected periodically from a subset of participants receiving immediate and deferred ART. We will use these data for modeling the impact of ART on infectivity during acute and recent HIV infection through various modes of exposure.
Viral phylogenetic analysis. We are mapping behavioral data (such as alcohol use) and geographic data onto phylogenetic transmission clusters to gain insights into drivers of HIV transmission in this population. This approach will allow us to determine the relative contributions of MSM and TW, with and without alcohol-use disorder (or other risk behaviors), to onward HIV transmission.
Modeling the expected intervention impact at the population level. The culmination of these analyses will be the development of an HIV epidemic model. We will use study data to estimate the percentage of HIV infections that are diagnosed as acute or recent and the distribution of testing intervals among MSM and TW overall. A series of deterministic models will be developed to simulate HIV transmission in Peruvian MSM and TW populations with and without our interventions, and to evaluate the public health impact of increased detection and treatment of acute and recent HIV infections on the HIV epidemic. A costeffectiveness evaluation will provide information to inform prevention strategies such as the one we have evaluated.
Association of HIV testing strategies and linkage to care using peer navigators. We will assess the overall impact of study activities on increasing the frequency of HIV testing among highrisk MSM and TW. Ninety percent of participants with early HIV infection were linked to the study clinics, within a median of 6 days. This compares very favorably with linkage-to-care rates for MSM and TW from this population who are referred to HIV care in the absence of study interventions-only 45% were linked to care within 90 days after testing positive (23) .
Context
This project has demonstrated that it is possible to reach a target population of high-risk MSM and TW, screen them for HIV, and then frequently retest those who are initially HIV-negative in order to identify incident cases shortly after HIV acquisition. Recruitment for HIV screening was accomplished through enhancing an existing platform for outreach in neighborhoods, and HIV testing was performed at clinics that are regularly visited by MSM and TW residents of Lima. Similarly, follow-up testing and treatment was performed at those same clinics. All other study activities were conducted with only slight modifications to the existing public health infrastructure within the community.
Implications
While current WHO guidelines call for initiation of ART at the time of HIV diagnosis, this alone does not guarantee early treatment, since most people are diagnosed years after HIV acquisition. Recent studies suggest that HIV reservoirs can be limited if treatment is begun in the weeks after HIV acquisition (24) and suggest that this would reduce onward transmission (25, 26) ; however, detecting infection this early remains a huge operational challenge. The Sabes Study sought to address this gap in public health practice by exploring the feasibility and impact of early HIV detection and treatment. Results to date have demonstrated the feasibility of detecting HIV infection shortly after acquisition with rapid linkage to care through community outreach and use of local clinics serving MSM and TW. Additional follow-up of these study participants has been instituted and will provide further insight into the benefits of early treatment initiation for individuals and the community.
